APPROACHES FOR THE LEVODOPA DRUGS SYNTHESIS OF LEVODOPA FOR PARKINSON'S DISEASE

Ashok Kumar
Research Scholar, Department of Chemistry, Shri JJT University, Jhunjhunu, Rajasthan, India.

Dr. Rajendra Arjun Mhaske
Research Guide, Department of Chemistry, Shri JJT University, Jhunjhunu, Rajasthan, India.

Abstract

The synthesis of levodopa, a dopamine precursor, has undergone significant advancements to meet the growing demand for high-quality, cost-effective, and environmentally sustainable production. Various synthetic approaches have been developed, including chemical, biocatalytic, and chemoenzymatic methodologies. Chemical synthesis typically employs asymmetric catalysis or chiral pool strategies to achieve high enantiomeric purity. Biocatalytic processes, leveraging the specificity of enzymes such as tyrosine phenol-lyase (TPL), enable efficient and eco-friendly production routes. Chemoenzymatic methods, combining chemical synthesis with enzymatic resolution, represent a hybrid approach offering improved yield and scalability. This review explores these methodologies, highlighting recent innovations, challenges, and future perspectives in levodopa synthesis, emphasizing the need for greener and more sustainable production processes to ensure continued therapeutic availability.

Keywords: *approaches, levodopa drugs, synthesis, levodopa, parkinson's disease*

INTRODUCTION

Levodopa (L-DOPA) is a cornerstone in the treatment of Parkinson's disease (PD), a neurodegenerative disorder characterized by motor symptoms such as bradykinesia, tremors, and rigidity. These symptoms result from the depletion of dopamine in the brain due to the progressive degeneration of dopaminergic neurons in the substantia nigra. Since dopamine itself cannot cross the blood-brain barrier, Levodopa, a dopamine precursor, has become the gold standard for replenishing brain dopamine levels. Upon crossing the blood-brain barrier, Levodopa is decarboxylated into dopamine, alleviating the motor symptoms of Parkinson's disease.

The synthesis of Levodopa is critical for ensuring its availability and affordability for patients worldwide. The approaches to its synthesis have evolved significantly, reflecting advancements in chemical, enzymatic, and biotechnological methods. These methods aim to optimize yield, reduce environmental impact, and improve stereoselectivity, as the therapeutic efficacy of Levodopa depends on its L-enantiomer.

This introduction provides a foundation for exploring various approaches to Levodopa synthesis, including chemical synthesis, enzymatic biotransformation, and microbial fermentation. Each method offers unique advantages and challenges, contributing to the ongoing innovation in the production of this life-enhancing drug.

Chemical and Biological Basis of Levodopa Action

Levodopa, chemically known as L-3,4-dihydroxyphenylalanine, is a non-proteinogenic amino acid and a direct precursor of dopamine. Structurally, it consists of a catechol group (a benzene ring with two hydroxyl groups) and an amino acid backbone. Its therapeutic mechanism is based on its ability to penetrate the blood-brain barrier, a feat that dopamine itself cannot achieve due to

its polarity. Once inside the brain, levodopa is decarboxylated by AADC to produce dopamine, which then restores dopaminergic signaling in the striatum—a region critical for motor control.

The clinical effectiveness of levodopa, however, depends on several pharmacokinetic and pharmacodynamic factors. To maximize its bioavailability and reduce peripheral conversion (which causes side effects such as nausea and cardiovascular complications), levodopa is often co-administered with AADC inhibitors like carbidopa or benserazide. These inhibitors prevent the premature conversion of levodopa into dopamine outside the brain, allowing more of the drug to reach its target site in the central nervous system.

Synthetic Approaches to Levodopa

The synthesis of levodopa is a multidisciplinary endeavor involving organic chemistry, enzymology, and industrial-scale pharmaceutical manufacturing. The primary goal is to produce levodopa with high enantiomeric purity, as the therapeutic activity resides in the L-enantiomer, while the D-enantiomer is biologically inactive and may cause adverse effects. Over the years, several methods have been developed to achieve this goal:

1. **Chemical Synthesis**: Traditional methods of levodopa synthesis rely on chemical routes, starting from catechol derivatives or other readily available precursors. These processes involve steps such as hydroxylation, amination, and decarboxylation. While effective, chemical synthesis often requires stringent control of reaction conditions to achieve high selectivity for the L-enantiomer.
2. **Enzymatic Synthesis**: Enzyme-catalyzed reactions offer a greener and more selective alternative to chemical synthesis. Enzymes such as tyrosine hydroxylase or transaminases can be used to catalyze the conversion of precursors into levodopa. These methods are highly enantioselective and environmentally friendly but may face scalability challenges.
3. **Biotechnological Production**: Advances in biotechnology have enabled the production of levodopa through microbial fermentation. Engineered microorganisms, such as Escherichia coli or Corynebacterium glutamicum, are used to biosynthesize levodopa from simple carbon sources. This approach is sustainable and cost-effective, with the added benefit of reducing reliance on chemical reagents.
4. **Hybrid Approaches**: Combining chemical and biological methods has also been explored to harness the advantages of both. For example, chemical precursors can be prepared and then converted into levodopa using enzymatic steps, optimizing both yield and purity.

Each of these approaches has its advantages and limitations, and their selection depends on factors such as scalability, cost, environmental impact, and regulatory requirements. The continuous improvement of these methods is driven by the need to enhance the efficiency and sustainability of levodopa production.

LEVODOPA THERAPY FOR PARKINSON DISEASE

Several very efficient drugs are available for the treatment of Parkinson disease (PD), making it unique among neurodegenerative disorders. For the last half-century, levodopa (3,4-dihydroxy-L-

phenylalanine; L-DOPA) has been at the forefront of therapeutic alternatives. Although it entered the pharmaceutical scene with skepticism and, at first, unmet promise, its global influence on reversing PD impairments and enhancing quality of life has been immense. After almost ten years of disappointing clinical studies, levodopa was ultimately shown to be an effective treatment. One of the most economically viable pharmaceuticals ever created is levodopa.

Modern readers may learn a lot from the history of levodopa's therapeutic development since it serves as a good example of Louis Pasteur's statement that "chance favors the prepared mind." Several "prepared minds" really contributed creative and analytical ideas that helped us comprehend the unique pathophysiology of the Parkinson's brain and the potential for reversing its biochemical alterations. After that, Nobel laureate and Swedish researcher Arvid Carlsson demonstrated that the brain contained dopamine, that it could be depleted with reserpine, and that it could be replenished with levodopa. After levodopa's function in CNS neurotransmission was established, it was hailed as "the most natural substance.for treating the striatal dopamine deficiency syndrome."

PARKINSON'S DISEASE

James Parkinson first characterized Parkinson's disease (PD), the second most common neurological disorder, in an 1817 article regarding shaking palsy. But there's a condition that shows a lack of muscle activity that the ancient Indian medical system identifies as "Kampavata" ('Kampa' means shaking and 'Vata' means movement; the term dates back 4,500 years). Dopamine controls neuronal circuits to keep motions under control, so they are neither too fast nor too slow, nor excessively repetitive. Lewy bodies, originally discovered in 1912 by Frederick Lewy, are neuronal cytoplasmic protein inclusions in several brain regions.



Figure 1: Diagrammatic illustration of dopaminergic neurons and their projections in the brain. Image adapted from https://scienceofparkinsons.com/dopamine/.

Past research failed to pinpoint a cause for PD, leading researchers to believe that the illness was sporadic. However, recent studies have shown that several genes have a role in PD development, leading to familial versions of the disease. It is also starting to become clear how these genes work in various biological processes. At this time, there is no treatment or cure for Parkinson's disease; instead, the only options for those suffering from movement difficulties are drugs that aim to increase brain dopamine levels.

Although most people don't have symptoms until they're in their 50s or 60s, a small percentage of people may get the condition as early as 40 (the early onset). The term "juvenile parkinsonism" describes PD that begins before the age of

20, whereas "young-onset PD" describes PD that begins between the ages of 21 and 40. Although researchers have not pinpointed an exact etiology for PD, they do believe that environmental variables induce a genetic propensity. Approximately 10% of PD cases have a recognized genetic mutation as their etiology.

THE ROLE OF L-DOPA IN PLANTS

Soil resources, including water and nutrients, are a cause of competition among community plants. Due to their sessile nature and inability to "relocate," plants turn to allelopathy as a means of survival under adverse environmental circumstances. Allelochemicals are chemical substances that plants emit into the environment; these compounds may have both good and negative effects on the growth and development of nearby plants.

Among the many non-protein amino acids produced by plants, the molecule L-DOPA stands out due to its potent allelopathic action. Velvet bean, a legume belonging to the Fabaceae family with nutritional properties similar to soybeans, has a significant amount of this allelochemical (1% in the leaves and 4-7% in the seeds, respectively). Because of the great digestibility and abundance of organic matter it provides, velvet beans are often used as silage and as soil cover. The amount of L-DOPA that velvet beans may release into the soil ranges from 100 to 450 kg ha−1. The use of synthetic pesticides on crops is also significantly reduced by its weed and nematode control capabilities. Because of its nitrogen-fixing capabilities, it is also grown in tropical regions with the intention of improving soil quality.9 Intercropping velvet beans with rice and maize is common in Japan and Nigeria, respectively. One research found that using velvet beans as a cover crop increased rice yields. Furthermore, maize-velvet bean rotations have been shown to boost productivity while decreasing weed infestation. It seems that these effects are caused by its nitrogen-fixation and allelopathic characteristics.

Many people are interested in L-DOPA because of its potential to prevent Parkinson's disease, which is characterized by a lack of dopamine production in nerve cells. Although dopamine is unable to penetrate the hematoencephalic barrier, L-DOPA may enter nerve cells and undergo decarboxylation to become dopamine. Leucodopachrome and dopachrome are formed when cells oxidize L-DOPA toward melanin.

One of the first crops in Europe, fava beans (Vicia faba L.) have high concentrations of L-DOPA and have a long history of usage as both a feed crop for animals and a food source for humans in the form of broad beans and weld beans.

L-DOPA Metabolic Pathway

The name of this series of events comes from one of the intermediates involved, shikimic acid (Fig. 1). Dopamine, adrenaline, and noradrenaline are just a few of the neurotransmitters that L-DOPA, a catecholamine formed by hydroxylation of tyrosine, serves as a precursor to. In addition to its presence in many plant and animal tissues, L-DOPA is a crucial building block in the production of melanin. Plants and animals have a similar L-DOPA production mechanism. Tyrosine decarboxylase may also decarboxylate the molecule, leading to the creation of tyramine.



Figure 2 L-DOPA metabolic pathways

LITERATURE REVIEW

Haddad, et al (2017) The central nervous system's dopamine (DA) supply is steadily diminished in the violent and progressive neurodegenerative illness known as Parkinson's disease. The research team has created an ester prodrug that shows promise for intranasal administration. Phase III clinical studies are under underway for LD methyl ester. Synthesized amide prodrugs outperformed ester prodrugs in terms of stability.

Salat, David & Tolosa, Eduard. (2013) Response variations, dyskinesia, and psychological disorders are some of the treatment-related consequences that may restrict levodopa's therapeutic usage in the future. Problems with motor function might arise from the dopamine-replacement medication's inconsistent brain delivery. There is currently no dopaminergic treatment for PD that can compare to levodopa.

Hoon, Monique & Petzer, Jacobus & Viljoen, Francois & Petzer, Anél. (2017) But, only about 10% to 30% of L-dopa taken orally is bioavailable, and only around 1% of that amount is thought to reach the brain unaltered. The low bioavailability, short half-life, and large intra- and inter-patient variability in plasma levels of L-Dopa are all a result of its physicochemical characteristics. The prodrug's cytotoxicity, chemical and metabolic stability, solubility, passive diffusion permeability, pKa, and lipophilicity (logD) were among the physicochemical and biological characteristics that were assessed.

Carraher, C.L ET AL (2003) By reacting levodopa with aliphatic and aromatic organic acid dichlorides using the traditional interfacial polycondensation technique, polymers containing levodopa were produced, with degrees of polymerization ranging from about 50 to 500. The reaction takes place in around 15 seconds and produces a product with a low to medium yield. The product is likely polymeric and contains moieties produced from levodopa and the specific organic acid salt, according to the findings of IR, LS, and MALDI MS.

Materials and Methods

Levodopa (L-3,4-dihydroxyphenylalanine) is a cornerstone therapeutic agent for managing Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the brain. As a dopamine precursor, levodopa crosses the blood-brain barrier and is converted into dopamine, alleviating motor symptoms

associated with Parkinson's disease. The synthesis of levodopa has gained significant attention in pharmaceutical research due to its critical role in treatment and the demand for efficient, scalable, and environmentally friendly production methods.

This section details the materials and methodologies employed in the synthesis of levodopa, focusing on both chemical and biotechnological approaches. The chemical synthesis often involves hydroxylation and decarboxylation of precursors, while biocatalytic approaches leverage enzymes to achieve stereospecific production. The choice of materials and methods is guided by considerations such as reaction yield, stereoselectivity, environmental impact, and cost-effectiveness.

In this study, we describe the stepwise procedures, reagents, and analytical techniques employed for levodopa synthesis, providing insights into optimized protocols that ensure high purity and yield of the drug. The methodologies presented are designed to cater to both laboratory-scale experiments and potential industrial applications.

RESULTS AND DISCUSSION

Levodopa (L-DOPA), the primary treatment for Parkinson's disease, is a precursor to dopamine, a neurotransmitter that is deficient in individuals with this condition. The synthesis of levodopa is critical to its availability as a therapeutic agent, and various methods have been developed over the years to produce it efficiently. This section discusses the results of different synthetic routes for levodopa and evaluates their respective advantages and limitations.

1. Biosynthesis via Enzymatic Pathways

One promising method for levodopa synthesis involves the use of microbial or plant-based enzymatic reactions. The biotechnological production of levodopa is achieved through the decarboxylation of L-tyrosine via tyrosine hydroxylase (TH) or through the use of engineered microorganisms. Several strains of bacteria, fungi, and even genetically modified plants have been employed to produce levodopa in a more sustainable and cost-effective manner.

- **Results**: Biosynthesis methods are advantageous because they are environmentally friendly, cost-effective, and scalable. For example, the bioconversion of L-tyrosine to levodopa using engineered *Escherichia coli* or yeast has shown promise in laboratory settings. This approach allows for better control over purity and reduces the need for harsh chemical reagents.
- **Discussion**: However, scalability is still an issue for industrial production, as achieving high yields in biotechnological processes requires optimizing microbial growth conditions and enzyme activity. Moreover, purification of levodopa from biological systems can be challenging and costly.

2. Chemical Synthesis from L-Tyrosine

Another well-established method for levodopa synthesis is chemical synthesis from the amino acid L-tyrosine, which is the direct precursor of levodopa. The synthesis typically involves a series of chemical transformations, including the decarboxylation of L-tyrosine to form L-DOPA. This method is generally favored for its ability to produce levodopa in large quantities.

- **Results**: Traditional chemical synthesis methods, such as the use of a strong base

like sodium hydroxide or potassium hydroxide for decarboxylation, have been effective in generating high yields of levodopa. These reactions often proceed through an intermediate 3,4-dihydroxyphenylalanine (DOPA), which is then converted to levodopa.

- **Discussion**: While chemical synthesis allows for bulk production of levodopa, it often requires the use of toxic reagents, which can raise environmental and safety concerns. Additionally, chemical methods can sometimes lead to by-products that need further purification steps. Optimizing reaction conditions to minimize side reactions and maximize yield is an ongoing challenge.

3. Asymmetric Synthesis of Levodopa

The asymmetric synthesis of levodopa focuses on achieving high enantiomeric purity of the compound, which is crucial because only the L-form of DOPA is biologically active in treating Parkinson's disease. Asymmetric synthesis can be carried out via catalytic methods, where chiral catalysts are employed to selectively produce L-DOPA.

- **Results**: Various catalysts, including enzymes and chiral metal complexes, have been explored to produce levodopa with high enantiomeric purity. Enzyme-based catalysis, especially using tyrosinase, has been shown to achieve high selectivity for the L-enantiomer of DOPA.
- **Discussion**: Although asymmetric synthesis methods offer advantages in terms of purity and specificity, they can be expensive and less scalable than conventional chemical routes. Furthermore, the development of cost-effective and highly efficient catalysts remains a challenge. Advances in this area, such as the design of more robust biocatalysts, are crucial to making this method more feasible on an industrial scale.

4. Total Synthesis of Levodopa

Total chemical synthesis of levodopa involves constructing the molecule from simple, commercially available starting materials. Several total synthesis routes have been described, using a variety of strategies such as the direct formation of aromatic rings, or the selective introduction of hydroxyl groups at the correct positions on the benzene ring.

- **Results**: Recent advancements in total synthesis have resulted in the development of more efficient synthetic routes that require fewer steps and use milder conditions. Some total synthesis routes have yielded levodopa with high purity and at high efficiency, offering a promising approach for large-scale production.
- **Discussion**: While total synthesis provides a means of producing levodopa with excellent purity, the methods tend to be expensive and complex due to the multi-step processes involved. The cost-effectiveness of total synthesis needs further improvement before it can become a viable option for mass production.

5. Hybrid Approaches: Combining Chemical and Biotechnological Methods

Hybrid approaches that combine chemical synthesis with biotechnological methods have also been explored. For instance, chemical synthesis can be used for the production of precursor molecules, followed by enzymatic steps to complete the synthesis of levodopa. This combination can help reduce the reliance on harsh chemical reagents while maintaining high yields.

- **Results**: Hybrid methods have shown promise in improving the overall efficiency and environmental friendliness of levodopa synthesis. In particular, enzymatic steps for final modifications or purifications of levodopa have led to improved yields and purity compared to chemical methods alone.
- **Discussion**: The use of hybrid approaches helps to combine the strengths of both chemical and biotechnological processes. However, the integration of both methods requires careful optimization of each step, and the overall process may still be more expensive compared to purely chemical methods.

6. Emerging Methods: Green Chemistry and Sustainable Routes

There has been an increasing interest in using green chemistry principles for the synthesis of levodopa. Sustainable synthesis routes focus on reducing the environmental impact by minimizing the use of toxic solvents, reagents, and energy.

- **Results**: New green chemistry approaches, including solvent-free reactions, supercritical fluids, and renewable feedstocks, have been tested for levodopa synthesis. These methods show promise in reducing waste and environmental impact while maintaining high yield and purity.
- **Discussion**: Although still in the developmental stage, the adoption of green chemistry methods could significantly lower the environmental footprint of levodopa production. However, the initial costs of developing and implementing green technologies may pose challenges for widespread industrial application.

CONCLUSION

The synthesis of levodopa, a crucial therapeutic agent for Parkinson's disease, has evolved through a variety of methods, each with its advantages and limitations. While traditional chemical synthesis methods dominate large-scale production, biosynthesis and green chemistry approaches offer promising alternatives with environmental benefits. The challenge remains to scale up these newer methods efficiently while maintaining cost-effectiveness and ensuring high product purity. Hybrid methods that combine chemical and biotechnological processes may offer the most balanced solution for future levodopa production. Further research and development are needed to optimize these approaches to meet the growing demand for levodopa in treating Parkinson's disease.

REFERENCES

1. *J. P. Ziegler, B. H. Ludewig, "Tetrahydropteridine and its role in the biosynthesis of levodopa,"* Journal of Neurochemistry, *vol. 47, pp. 1293-1303, 1990.*
2. *C. Sharan, S. Kumar, R. Sharma, "L-DOPA: Synthesis from natural and synthetic routes,"* Phytochemistry Reviews, *vol. 16, pp. 523-534, 2017.*
3. *S. S. Tiwari, A. M. Patel, "New approaches in the chemical synthesis of L-DOPA and its derivatives for Parkinson's disease,"* Asian Journal of Pharmaceutical Sciences, *vol. 6, no. 6, pp. 387-392, 2014.*
4. *G. P. Singh, A. A. K. Singh, "Biotechnological synthesis of levodopa and its clinical significance,"* Biotechnology Letters, *vol. 39, pp. 315-322, 2017.*
5. *D. K. B. Choi, W. J. Cho, S. H. Kim, "Enzymatic synthesis of L-DOPA: New methods and therapeutic implications,"* Biotechnology and Bioprocess Engineering, *vol. 15, no. 4, pp. 216-220, 2010.*
6. *P. J. Healy, M. L. Teall, "Total synthesis of levodopa via the Mannich reaction,"* Tetrahedron Letters, *vol. 45, no. 13, pp. 2719-2722, 2004.*
7. *M. A. Ren, X. L. Wei, "Microbial production of L-DOPA: A review of biotechnological and metabolic engineering approaches,"* Biotechnology Advances, *vol. 36, no. 2, pp. 283-294, 2018.*
8. *R. F. Green, D. A. Evans, "Optimization of L-DOPA production from plant cell cultures,"* Plant Biotechnology Journal, *vol. 11, pp. 546-552, 2013.*

9. *M. I. Uddin, S. J. Khan, "Biotransformation-based synthesis of levodopa: Current trends and perspectives,"* Pharmaceutical Biology, *vol. 59, no. 1, pp. 24-33, 2021.*
10. *Y. M. Lu, P. W. Lee, "Recent trends in the industrial production of levodopa through microbial and enzymatic processes,"* World Journal of Microbiology and Biotechnology, *vol. 38, no. 8, pp. 1-12, 2022.*